Lilly’s retatrutide beats Ozempic in head-to-head trial
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 28 13:26 ETSource: Clinical Trials Arena
From the source
Read at clinicaltrialsarena.comLilly’s retatrutide beats Ozempic in head-to-head trial
Prescribed peptides from $99/moSee all →